K. Rajender Reddy - JoVE Visualize

Showing results (211-220 of 415) with videos related to

Pageof 42

Sort By:

Journal of Hepatology|September 20, 2005

Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensationScott K Fung, Pietro Andreone, Steve H Han, et al.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 29, 2020

Patient Characteristics and Outcomes of 11 721 Patients With Coronavirus Disease 2019 (COVID-19) Hospitalized Across the United StatesMichael W Fried, Julie M Crawford, Andrea R Mospan, et al.

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 21, 2017

Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without VoxilaprevirZobair M Younossi, Maria Stepanova, Stuart Gordon, et al.

Liver International : Official Journal of the International Association for the Study of the Liver|March 26, 2014

Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN)Paul H Hayashi, Huiman X Barnhart, Robert J Fontana, et al.

Epidemiology (Cambridge, Mass.)|January 31, 2023

Effectiveness of Remdesivir Treatment Protocols Among Patients Hospitalized with COVID-19: A Target Trial EmulationAlexander Breskin, Catherine Wiener, Adaora A Adimora, et al.

Journal of Viral Hepatitis|October 10, 2012

Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirinS Zeuzem, M Rodríguez-Torres, K Rajender Reddy, et al.

Transplantation|April 30, 2003

Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudineJose R Nery, Caio Nery-Avila, K Rajender Reddy, et al.

Journal of Hepatology|September 10, 2002

Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)Samuel S Lee, E Jenny Heathcote, K Rajender Reddy, et al.

The American Journal of Gastroenterology|June 18, 2003

Comparison of three commercially available assays for HCV RNA using the international unit standard: implications for management of patients with chronic hepatitis C virus infection in clinical practiceMitchell L Shiffman, Andrea Ferreira-Gonzalez, K Rajender Reddy, et al.

The American Journal of Gastroenterology|July 6, 2004

Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trialPaul J Pockros, Robert Carithers, Paul Desmond, et al.

Pageof 42

Showing results (211-220 of 415) with videos related to

Sort By:

Pageof 42

Journal of Hepatology|September 20, 2005

Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensationScott K Fung, Pietro Andreone, Steve H Han, et al.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 29, 2020

Patient Characteristics and Outcomes of 11 721 Patients With Coronavirus Disease 2019 (COVID-19) Hospitalized Across the United StatesMichael W Fried, Julie M Crawford, Andrea R Mospan, et al.

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 21, 2017

Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without VoxilaprevirZobair M Younossi, Maria Stepanova, Stuart Gordon, et al.

Liver International : Official Journal of the International Association for the Study of the Liver|March 26, 2014

Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN)Paul H Hayashi, Huiman X Barnhart, Robert J Fontana, et al.

Epidemiology (Cambridge, Mass.)|January 31, 2023

Effectiveness of Remdesivir Treatment Protocols Among Patients Hospitalized with COVID-19: A Target Trial EmulationAlexander Breskin, Catherine Wiener, Adaora A Adimora, et al.

Journal of Viral Hepatitis|October 10, 2012

Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirinS Zeuzem, M Rodríguez-Torres, K Rajender Reddy, et al.

Transplantation|April 30, 2003

Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudineJose R Nery, Caio Nery-Avila, K Rajender Reddy, et al.

Journal of Hepatology|September 10, 2002

Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)Samuel S Lee, E Jenny Heathcote, K Rajender Reddy, et al.

The American Journal of Gastroenterology|June 18, 2003

Comparison of three commercially available assays for HCV RNA using the international unit standard: implications for management of patients with chronic hepatitis C virus infection in clinical practiceMitchell L Shiffman, Andrea Ferreira-Gonzalez, K Rajender Reddy, et al.

The American Journal of Gastroenterology|July 6, 2004

Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trialPaul J Pockros, Robert Carithers, Paul Desmond, et al.

Pageof 42